Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of surgical treatment of FTMH using an inverted ILM repositioning to improve anatomical and functional outcomes in patients with a macular hole.
At present, the anatomical closure rate of macular hole is around 90% using pars plana vitrectomy with ILM peeling. Improvement of visual acuity is around 80% including stage II to IV. With macular hole greater than 400 μm there is higher risk of surgical failure and visual acuity is usually less than 0.2. Large macular holes are more likely to have flat-open type closure, which is anatomical success but has limited improvement in visual acuity. Inverted ILM repositioning will form a scaffold for glial cells, which allows their migration and proliferation. This process will close the macular hole and secure it from re-opening, and will reduce the risk of flat-open type of closure.
The aim of this study is to estimate the efficiency and safety of inverted ILM repositioning in the treatment of macular hole with a minimum diameter exceeding 400 μm and compare results with the currently used methods of surgical large macular holes treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Idiopathic Full Thickness Macular Hole | Experimental | Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inverted ILM Repositioning | Procedure | Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation. |
| Measure | Description | Time Frame |
|---|---|---|
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | up to 1 week before surgery |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | 2 weeks postoperatively ( plus or minus 1 week) |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | 4 weeks postoperatively ( plus or minus 1 week) |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | 6 weeks postoperatively ( plus or minus 1 week) |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | 12 weeks postoperatively ( plus or minus 1 week) |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. |
| Measure | Description | Time Frame |
|---|---|---|
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | up to 1 week before surgery |
| Central Macular Thickness (CMT), Central Macular Volume |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jacek Robaszkiewicz, dr med. | Contact | +48 604597970 | vectra@izet.pl | |
| Urszula Karpińska, lek. med. | Contact | +48 668335961 | bequille@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jacek Robaszkiewicz, dr med. | Department of Ophthalmology Military Institute of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Military Institute of Medcine | Recruiting | Warsaw | Ul. Szaserów 128 | 04-141 | Poland |
Not provided
| ID | Term |
|---|---|
| D012167 | Retinal Perforations |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| 24 weeks postoperatively ( plus or minus 1 week) |
| Best-corrected visual acuity (BCVA), postoperative macular hole closure type | BCVA for ETDRS chart (converted to logMAR) and postoperative macular hole closure type assessed by OCT: elevated-open, flat-open and flat-closed. | 48 weeks postoperatively ( plus or minus 1 week) |
Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). |
| 2 weeks postoperatively (plus and minus 1 week) |
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | 4 weeks postoperatively (plus and minus 1 week) |
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | 6 weeks postoperatively (plus and minus 1 week) |
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | 12 weeks postoperatively (plus and minus 1 week) |
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | 24 weeks postoperatively (plus and minus 1 week) |
| Central Macular Thickness (CMT), Central Macular Volume | Central Macular Thickness (CMT)and Central Macular Volume are assessed 1 mm and 6 mm diameter topography (OCT-SLO). | 48 weeks postoperatively (plus and minus 1 week) |